| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | リウマチ性
> シェーグレン症候群 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | 内分泌
> 副腎および下垂体疾患 | 規制上のパートナーシップ
> マーケティング承認申請への貢献 | 100 | National | Rarely | 119052076100 |
| We are engaged in formal consultation processes. | 内分泌
> 糖尿病（1型および2型の両方） | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | Do not know | National | Rarely | 119035824614 |
| Advisory board of Swissmedic. | がん
> がん：肺 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Sometimes | 119061399060 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | リウマチ性
> シェーグレン症候群 | 規制上のパートナーシップ
> 他の医療擁護者と | We do not communicate with patients directly | International | Regularly | 119025245981 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | スキン
> 血管性浮腫 | 規制上のパートナーシップ
> 他の医療擁護者と | 100 | National | Sometimes | 119052980204 |
| Via our umbrella organisation HOPOS [Hemato-Onkologische Patientenorganisationen Schweiz - Swiss Umbrella Organisation of Haemato-Oncological Patient Organisations]. | がん
> がん：血液 | 規制上のパートナーシップ
> 他の医療擁護者と | 1,000 | National | Rarely | 119077844806 |
| To advocate for the establishment of an information policy directed at local authorities. | がん
> がん：前立腺 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100 | Regional | Sometimes | 115056429435 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. | リウマチ性
> シェーグレン症候群 | 政策と法律への影響
> 医療政策と法律に影響を与える | We do not communicate with patients directly | International | Regularly | 119025245981 |
| Legislative adaptation through ongoing communication. | レア
> 希少疾患：子ども・若者 | 政策と法律への影響
> 医療政策と法律に影響を与える | 1,000 | National | Sometimes | 119035891744 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | 患者教育
> 患者教育 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100 | National | Sometimes | 119035955624 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | がん
> がん：前立腺 | 政策と法律への影響
> 医療政策と法律に影響を与える | 1,000 | National | Regularly | 119044110604 |
| Advocacy representation in relation to the new care legislation. | 神経変性
> アルツハイマー病 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100,000 | National | Regularly | 119044141359 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | 患者教育
> 患者教育 | 政策と法律への影響
> 公衆衛生法の立案に貢献する | 100 | National | Sometimes | 119035955624 |
| Advocacy representation in relation to the new care legislation. | 神経変性
> アルツハイマー病 | 政策と法律への影響
> 公衆衛生法の立案に貢献する | 100,000 | National | Regularly | 119044141359 |
| Support with formal cost-approval (reimbursement authorisation) applications and with newly introduced restrictions on treatment options. | 心臓血管
> 家族性高コレステロール血症（FH） | 政策と法律への影響
> 医療における障壁・異常への対処 | 100 | National | Sometimes | 119072887138 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | リウマチ性
> シェーグレン症候群 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | がん
> がん：肺 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Support with reimbursement approvals. | 心臓血管
> 家族性高コレステロール血症（FH） | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 100 | National | Sometimes | 119072887138 |
| Primarily through public appeals, media coverage, and similar channels [on issues of drug pricing]. | HIV
> HIV | 価格設定と手頃な価格の擁護
> 啓発キャンペーンへの参加 | 5,000 | National | Rarely | 119035314201 |
| Assisting a family in accessing a medication covered by their insurance. | 神経学的
> 神経線維腫症（NF） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100 | Regional | Rarely | 115023088362 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | スキン
> 血管性浮腫 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100 | National | Sometimes | 119052980204 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | がん
> がん：肺 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | リウマチ性
> シェーグレン症候群 | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | 内分泌
> 副腎および下垂体疾患 | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | 100 | National | Rarely | 119052076100 |
| ... Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | リウマチ性
> シェーグレン症候群 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | がん
> がん：肺 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | がん
> がん：肺 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | スキン
> 血管性浮腫 | エビデンスに基づく患者の意見
> エビデンスとインサイトを政策インプットに変換する | 100 | National | Sometimes | 119052980204 |
| Participation in the RDA [Research Data Alliance]-Forum / CTA [Clinical Trial Authorisation] activities. | リウマチ性
> 強皮症 | 診断と薬の配達
> 臨床試験デザインの共同作業 | 100 | National | Rarely | 119056569513 |
| Through physicians, hospitals, and participation in PPI [Patient and Public Involvement] meetings. | がん
> がん：小児・若者向け | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 100 | National | Sometimes | 115032067078 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | がん
> がん：前立腺 | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 1,000 | National | Regularly | 119044110604 |
| We are a non-profit (ZEWO [Zentralstelle für Wohlfahrtsunternehmen - Central Office for Welfare Organisations]-certified) organisation. | メンタルヘルス
> うつ病 | 機関ガバナンス
> 公益法人または慈善団体としての正式な地位を維持する | 1,000 | Regional | No | 119063159875 |
| Support for obtaining AI [Assurance Invalidité – Disability Insurance]. | 視覚障害
> 視覚障害 | 患者の権利の擁護/生活の質の向上
> 患者体験の保護・改善 | 100 | Regional | Sometimes | 114996630534 |
インタラクション
アクションと支援活動
7 メンション
